Peter Olagunju

Mr. Olagunju was appointed as Chief Technical Officer at TCR² in 2021, leveraging his 20+ years of experience in cell and gene therapy, clinical development, program management, manufacturing, and technical operations. Prior to TCR², he served as Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of gene therapy for bladder cancer. At bluebird bio, Inc., he served as Vice President of Global Patient Operations, held various roles of increasing responsibility, and led the program and functional manufacturing team supporting the European approval for ZYNTEGLO®, a revolutionary gene therapy for Transfusion Dependent Thalassemia. Before that, he held senior positions in Commercial Technical Operations and served as Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an MBA from the University of Washington and a BS in Biology from the University of Illinois at Urbana-Champaign.